HSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative Neoplasms

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Sevin, Margaux ^a,b   Girodon, François ^a,b,c   Garrido, Carmen ^a,b,d   De Thonel, Aurélie ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c Service d'Hematologie   (France)

^d CGFL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 70 INHIBITOR; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; UNCLASSIFIED DRUG; AUTACOID;

CLINICAL TRIAL (TOPIC); HUMAN; INFLAMMATION; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; METABOLISM; MOLECULARLY TARGETED THERAPY; MYELOPROLIFERATIVE DISORDERS; SIGNAL TRANSDUCTION;

HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INFLAMMATION MEDIATORS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; MYELOPROLIFERATIVE DISORDERS; SIGNAL TRANSDUCTION;

EID: 84946053539     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/970242     Document Type: Review

References (81)

1. E. J. Baxter, L. M. Scott, P. J. Campbell et al., "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders," The Lancet, vol. 365, no. 9464, pp. 1054-1061, 2005.
2. C. James, V. Ugo, J.-P. Le Couédic et al., "A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera," Nature, vol. 434, no. 7037, pp. 1144-1148, 2005.
3. R. Kralovics and R. C. Skoda, "Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders," Blood Reviews, vol. 19, no. 1, pp. 1-13, 2005.
4. R. L. Levine, M. Wadleigh, J. Cools et al., "Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, andmyeloidmetaplasia withmyelofibrosis," Cancer Cell, vol. 7, no. 4, pp. 387-397, 2005.
5. T. L. Lasho, A. Pardanani, and A. Tefferi, "LNK mutations in JAK2 mutation-negative erythrocytosis," The New England Journal of Medicine, vol. 363, no. 12, pp. 1189-1190, 2010.
6. F. Delhommeau, S. Dupont, V. Della Valle et al., "Mutation in TET2 inmyeloid cancers," The New England Journal of Medicine, vol. 360, no. 22, pp. 2289-2301, 2009.
7. F. Stegelmann, L. Bullinger, R. F. Schlenk et al., "DNMT3A mutations in myeloproliferative neoplasms," Leukemia, vol. 25, no. 7, pp. 1217-1219, 2011.
8. F. Ritossa, "Anewpuffing pattern induced by temperature shock and DNP in Drosophila," Experientia, vol. 18, no. 12, pp. 571-573, 1962.
9. M. J. Schlesinger, "Heat shockproteins," The Journal of Biological Chemistry, vol. 265, no. 21, pp. 12111-12114, 1990.
10. S. Jindal, "Heat shock proteins: applications in health and disease," Trends in Biotechnology, vol. 14, no. 1, pp. 17-20, 1996.
11. C. Garrido, S. Gurbuxani, L. Ravagnan, and G. Kroemer, "Heat shock proteins: endogenousmodulators of apoptotic cell death," Biochemical and Biophysical Research Communications, vol. 286, no. 3, pp. 433-442, 2001.
12. D. Lanneau, M. Brunet, E. Frisan, E. Solary, M. Fontenay, and C. Garrido, "Heat shock proteins: essential proteins for apoptosis regulation," Journal of Cellular and Molecular Medicine, vol. 12, no. 3, pp. 743-761, 2008.
13. C. Didelot, D. Lanneau, M. Brunet et al., "Interaction of heatshock protein 90β isoform (HSP90β) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiation," Cell Death and Differentiation, vol. 15, no. 5, pp. 859-866, 2008.
14. G. Jego, D. Lanneau, A. De Thonel et al., "Dual regulation of SPI1/PU.1 transcription factor by heat shock factor 1 (HSF1) during macrophage differentiation of monocytes," Leukemia, vol. 28, no. 8, pp. 1676-1686, 2014.
15. S. E. Craven, D. French, W. Ye, F. De Sauvage, and A. Rosenthal, "Loss of Hspa9b in zebrafish recapitulates the ineffective hematopoiesis of the myelodysplastic syndrome," Blood, vol. 105, no. 9, pp. 3528-3534, 2005.
16. J.-A. Ribeil, Y. Zermati, J. Vandekerckhove et al., "Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1," Nature, vol. 445, no. 7123, pp. 102-105, 2007.
17. A. de Thonel, J. Vandekerckhove, D. Lanneau et al., "HSP27 controls GATA- 1 protein level during erythroid cell differentiation," Blood, vol. 116, no. 1, pp. 85-96, 2010.
18. W. B. Pratt and D. O. Toft, "Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery," Experimental Biology and Medicine, vol. 228, no. 2, pp. 111-133, 2003.
19. L. Whitesell and S. L. Lindquist, "HSP90 and the chaperoning of cancer," Nature Reviews Cancer, vol. 5, no. 10, pp. 761-772, 2005.
20. P.-L. Hsu and S.-M. Hsu, "Abundance of heat shock proteins (hsp89, hsp60, and hsp27) in malignant cells of Hodgkin's disease," Cancer Research, vol. 58, no. 23, pp. 5507-5513, 1998.
21. P. George, P. Bali, P. Cohen et al., "Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3," Cancer Research, vol. 64, no. 10, pp. 3645-3652, 2004.
22. L. Shang and T. B. Tomasi, "The heat shock protein 90-CDC37 chaperone complex is required for signaling by types I and II interferons," The Journal of Biological Chemistry, vol. 281, no. 4, pp. 1876-1884, 2006.
23. L. Whitesell, E. G. Mimnaugh, B. De Costa, C. E. Myers, and L. M. Neckers, "Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation," Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 18, pp. 8324-8328, 1994.
24. J. Lewis, A. Devin, A. Miller et al., "Disruption of Hsp90 function results in degradation of the death domain kinase, receptorinteracting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-κB activation," The Journal of Biological Chemistry, vol. 275, no. 14, pp. 10519-10526, 2000.
25. A.-L. Joly, G. Wettstein, G. Mignot, F. Ghiringhelli, and C. Garrido, "Dual role of heat shock proteins as regulators of apoptosis and innate immunity," Journal of Innate Immunity, vol. 2, no. 3, pp. 238-247, 2010.
26. E.M. Creagh, R. J. Carmody, and T.G. Cotter, "Heat shock protein 70 inhibits caspase-dependent and -independent apoptosis in Jurkat T cells," Experimental Cell Research, vol. 257, no. 1, pp. 58-66, 2000.
27. E. Schmitt, A. Parcellier, S. Gurbuxani et al., "Chemosensitization by a non-apoptogenic heat shock protein 70-binding apoptosis-inducing factormutant," Cancer Research, vol. 63, no. 23, pp. 8233-8240, 2003.
28. L. M. Vargas-Roig, F. E. Gago, O. Tello, J. C. Aznar, and D. R. Ciocca, "Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy," International Journal of Cancer, vol. 79, no. 5, pp. 468-475, 1998.
29. A. Brondani Da Rocha, A. Regner, I. Grivicich et al., "Radioresistance is associated to increased Hsp70 content in human glioblastoma cell lines," International Journal of Oncology, vol. 25, no. 3, pp. 777-785, 2004.
30. S. Ray, Y. Lu, S. H. Kaufmann et al., "Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis," Journal of Biological Chemistry, vol. 279, no. 34, pp. 35604-35615, 2004.
31. M. Gallardo, S. Barrio, M. Fernandez et al., "Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera," Molecular Cancer, vol. 12, article 142, 2013.
32. F. Guo, C. Sigua, P. Bali et al., "Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells," Apoptosis, vol. 105, no. 3, pp. 1246-1255, 2005.
33. G. Jego, A. Hazoumé, R. Seigneuric, and C. Garrido, "Targeting heat shock proteins in cancer," Cancer Letters, vol. 332, no. 2, pp. 275-285, 2013.
34. C. De Boer, P. A. Meulman, R. J. Wnuk, and D. H. Peterson, "Geldanamycin, a new antibiotic," Journal of Antibiotics, vol. 23, no. 9, pp. 442-447, 1970.
35. J. G. Supko, R. L. Hickman, M. R. Grever, and L. Malspeis, "Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent," Cancer Chemotherapy and Pharmacology, vol. 36, no. 4, pp. 305-315, 1995.
36. J. Trepel, M. Mollapour, G. Giaccone, and L. Neckers, "Targeting the dynamic HSP90 complex in cancer," Nature Reviews Cancer, vol. 10, no. 8, pp. 537-549, 2010.
37. J. E. Lancet, I. Gojo, M. Burton et al., "Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia," Leukemia, vol. 24, no. 4, pp. 699-705, 2010.
38. P. Delmotte and J. Delmotte-Plaquee, "A new antifungal substance of fungal origin," Nature, vol. 171, no. 4347, article 344, 1953.
39. T. W. Schulte, S. Akinaga, S. Soga et al., "Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin," Cell Stress&Chaperones, vol. 3, no. 2, pp. 100-108, 1998.
40. P. A. Brough, W. Aherne, X. Barril et al., "4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer," Journal of Medicinal Chemistry, vol. 51, no. 2, pp. 196-218, 2008.
41. G. Chiosis, M. N. Timaul, B. Lucas et al., "A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells," Chemistry and Biology, vol. 8, no. 3, pp. 289-299, 2001.
42. E. Caldas-Lopes, L. Cerchietti, J.H. Ahn et al., "Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 20, pp. 8368-8373, 2009.
43. O.G. Best, N. Singh, C. Forsyth, and S. P. Mulligan, "The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway," British Journal of Haematology, vol. 151, no. 2, pp. 185-188, 2010.
44. L. Jin, C.-L. Xiao, C.-H. Lu et al., "Transcriptomic and proteomic approach to studying SNX-2112-induced K562 cells apoptosis and anti-leukemia activity in K562-NOD/SCID mice," FEBS Letters, vol. 583, no. 12, pp. 1859-1866, 2009.
45. Y. Okawa, T. Hideshima, P. Steed et al., "SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK," Blood, vol. 113, no. 4, pp. 846-855, 2009.
46. L. Ravagnan, S. Gurbuxani, S. A. Susin et al., "Heat-shock protein 70 antagonizes apoptosis-inducing factor," Nature Cell Biology, vol. 3, no. 9, pp. 839-843, 2001.
47. J. I.-J. Leu, J. Pimkina, A. Frank, M. E. Murphy, and D. L. George, "A small molecule inhibitor of inducible heat shock protein 70," Molecular Cell, vol. 36, no. 1, pp. 15-27, 2009.
48. A. J. Massey, D. S. Williamson, H. Browne et al., "A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells," Cancer Chemotherapy and Pharmacology, vol. 66, no. 3, pp. 535-545, 2010.
49. A.-L. Rérole, J. Gobbo, A. De Thonel et al., "Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy," Cancer Research, vol. 71, no. 2, pp. 484-495, 2011.
50. E. L. Davenport, A. Zeisig, L. I. Aronson et al., "Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma," Leukemia, vol. 24, no. 10, pp. 1804-1807, 2010.
51. H. Zhang and F. Burrows, "Targeting multiple signal transduction pathways through inhibition of Hsp90," Journal of Molecular Medicine, vol. 82, no. 8, pp. 488-499, 2004.
52. N. Adhikari, N. Charles, U. Lehmann, and J. L. Hall, "Transcription factor and kinase-mediated signaling in atherosclerosis and vascular injury," Current Atherosclerosis Reports, vol. 8, no. 3, pp. 252-260, 2006.
53. A. Salminen, T. Paimela, T. Suuronen, and K. Kaarniranta, "Innate immunity meetswith cellular stress at the IKK complex: regulation of the IKKcomplex by HSP70 and HSP90," Immunology Letters, vol. 117, no. 1, pp. 9-15, 2008.
54. V. Malhotra, T. P. Shanley, J.-F. Pittet, W. J. Welch, and H. R. Wong, "Geldanamycin inhibits NF-kappaB activation and interleukin-8 gene expression in cultured human respiratory epithelium," American Journal of Respiratory Cell and Molecular Biology, vol. 25, no. 1, pp. 92-97, 2001.
55. J. W. Rice, J. M. Veal, R. P. Fadden et al., "Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis," Arthritis and Rheumatism, vol. 58, no. 12, pp. 3765-3775, 2008.
56. J. Madrigal-Matute, O. López-Franco, L. M. Blanco-Colio et al., "Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis," Cardiovascular Research, vol. 86, no. 2, pp. 330-337, 2010.
57. G. Chen, P. Cao, and D. V. Goeddel, "TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90," Molecular Cell, vol. 9, no. 2, pp. 401-410, 2002.
58. T. J. Yun, E. K. Harning, K. Giza et al., "EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity," Journal of Immunology, vol. 186, no. 1, pp. 563-575, 2011.
59. S. Bruemmer-Smith, F. Stüber, and S. Schroeder, "Protective functions of intracellular heat-shock protein (HSP) 70-expression in patients with severe sepsis," Intensive Care Medicine, vol. 27, no. 12, pp. 1835-1841, 2001.
60. H. Chen, Y. Wu, Y. Zhang et al., "Hsp70 inhibits lipopolysaccharide-induced NF-κB activation by interacting with TRAF6 and inhibiting its ubiquitination," FEBS Letters, vol. 580, no. 13, pp. 3145-3152, 2006.
61. F. Chalmin, S. Ladoire, G. Mignot et al., "Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells," Journal of Clinical Investigation, vol. 120, no. 2, pp. 457-471, 2010.
62. S. S. Mambula and S. K. Calderwood, "Heat shock protein 70 is secreted from tumor cells by a nonclassical pathway involving lysosomal endosomes," Journal of Immunology, vol. 177, no. 11, pp. 7849-7857, 2006.
63. P. Srivastava, "Roles of heat-shock proteins in innate and adaptive immunity," Nature Reviews Immunology, vol. 2, no. 3, pp. 185-194, 2002.
64. J. Campisi, T. H. Leem, and M. Fleshner, "Stress-induced extracellular Hsp72 is a functionally significant danger signal to the immune system," Cell Stress and Chaperones, vol. 8, no. 3, pp. 272-286, 2003.
65. J. D. Johnson and M. Fleshner, "Releasing signals, secretory pathways, and immune function of endogenous extracellular heat shock protein 72," Journal of Leukocyte Biology, vol. 79, no. 3, pp. 425-434, 2006.
66. R. Njemini, M. Lambert, C. Demanet, M. V. Abeele, S. Vandebosch, and T. Mets, "The induction of heat shock protein 70 in peripheral mononuclear blood cells in elderly patients: a role for inflammatory markers," Human Immunology, vol. 64, no. 6, pp. 575-585, 2003.
67. A. G. Pockley, J. Shepherd, and J. M. Corton, "Detection of heat shock protein 70 (Hsp70) and anti-Hsp70 antibodies in the serumof normal individuals," Immunological Investigations, vol. 27, no. 6, pp. 367-377, 1998.
68. T. Torigoe, Y. Tamura, and N. Sato, "Heat shock proteins and immunity: application of hyperthermia for immunomodulation," International Journal of Hyperthermia, vol. 25, no. 8, pp. 610-616, 2009.
69. A. Asea, S.-K. Kraeft, E. A. Kurt-Jones et al., "HSP70 stimulates cytokine production through a CD 14-dependant pathway, demonstrating its dual role as a chaperone and cytokine," Nature Medicine, vol. 6, no. 4, pp. 435-442, 2000.
70. W. Fiskus, S. Verstovsek, T. Manshouri et al., "Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells," Clinical Cancer Research, vol. 17, no. 23, pp. 7347-7358, 2011.
71. W.G. An, T.W. Schulte, and L.M. Neckers, "The heat shockprotein 90 antagonist geldanamycin alters chaperone association with p210(bcr-abl) and v-src proteins before their degradation by the proteasome," Cell Growth and Differentiation, vol. 11, no. 7, pp. 355-360, 2000.
72. M. E. Gorre, K. Ellwood-Yen, G. Chiosis, N. Rosen, and C. L. Sawyers, "BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90," Blood, vol. 100, no. 8, pp. 3041-3044, 2002.
73. J. Bareng, I. Jilani, M. Gorre et al., "A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flowcytometry," Leukemia and Lymphoma, vol. 48, no. 11, pp. 2189-2195, 2007.
74. S. Marubayashi, P. Koppikar, T. Taldone et al., "HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans," The Journal of Clinical Investigation, vol. 120, no. 10, pp. 3578-3593, 2010.
75. L. C. Cerchietti, E. C. Lopes, S. N. Yang et al., "A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas," Nature Medicine, vol. 15, no. 12, pp. 1369-1376, 2009.
76. O. Weigert, A. A. Lane, L. Bird et al., "Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition," Journal of Experimental Medicine, vol. 209, no. 2, pp. 259-273, 2012.
77. N. Bhagwat, P. Koppikar, M. Keller et al., "Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms," Blood, vol. 123, no. 13, pp. 2075-2083, 2014.
78. T. Stühmer, A. Zöllinger, D. Siegmund et al., "Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVPAUY922 in multiple myeloma," Leukemia, vol. 22, no. 8, pp. 1604-1612, 2008.
79. S. A. Eccles, A. Massey, F. I. Raynaud et al., "NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis," Cancer Research, vol. 68, no. 8, pp. 2850-2860, 2008.
80. M. Kaiser, A. Kühnl, J. Reins et al., "Antileukemic activity of the HSP70 inhibitor pifithrin-l in acute leukemia," Blood Cancer Journal, vol. 1, no. 7, article e28, 2011.
81. S. Barrio, M. Gallardo, A. Arenas et al., "Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm," British Journal of Haematology, vol. 161, no. 5, pp. 667-676, 2013.